Roche joins the M&A game, buying gene therapy pioneer Spark for $4.3B
It's official. Roche is joining the multibillion-dollar M&A game, acquiring a top player in the booming gene therapy business.
Image: Spark CEO Jeffrey Marrazzo at an Endpoints News panel during the 2019 JP Morgan conference Jeff Rumans for Endpoints News
Basic subscription required
Unlock this story instantly and join 53,000+ biopharma pros reading Endpoints daily — and it's free.